GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $18.00 price objective on the stock.

GeoVax Labs Stock Down 7.3 %

Shares of NASDAQ GOVX opened at $1.27 on Friday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The stock’s fifty day simple moving average is $1.69 and its two-hundred day simple moving average is $2.16.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million. As a group, equities research analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp acquired a new stake in GeoVax Labs during the 4th quarter worth about $29,000. Geode Capital Management LLC lifted its position in GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the period. Virtu Financial LLC purchased a new stake in GeoVax Labs in the third quarter valued at $97,000. Finally, Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter worth about $104,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.